Clinical Trials Sponsored by Gustave Roussy, Cancer Campus, Grand Paris

Total 257 results

Gustave Roussy, Cancer Campus, Grand Paris

Completed

Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC

Oral Cancer | Oropharynx Cancer | Larynx Cancer | Hypopharynx Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
LinKinVax

Recruiting

Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer (HPVDCVax)

Head and Neck Carcinoma | Adult Disease

France
Gustave Roussy, Cancer Campus, Grand Paris
Sanofi

Unknown

Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer (CABA-DOC)

Metastatic Castration-resistant Prostate Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
Sanofi

Unknown

A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors (CABA-GCT)

Non-seminomatous Germ-cell Tumors

France
Gustave Roussy, Cancer Campus, Grand Paris
Bayer

Recruiting

Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma (REGO-EWING)

Bone Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca

Recruiting

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA)

Early Small (cT1N0) Triple Negative Breast Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca

Completed

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients (GEFTREM)

Non Small Cell Lung Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
Novartis

Unknown

Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer (RAD001)

Non-small Cell Lung Cancer | Locally Advanced Disease

France
Gustave Roussy, Cancer Campus, Grand Paris
European Commission

Completed

Identification of Early Markers of Response and Resistance to Trastuzumab (HERBIN)

Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo

Recruiting

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (ICARUSBREAST02)

Advanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast Carcinoma

France
Gustave Roussy, Cancer Campus, Grand Paris
Institut Curie

Completed

Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer (REMAGUS04)

Breast Cancer

France
University College, London
Gustave Roussy, Cancer Campus, Grand Paris

Not yet recruiting

Assessment of Novel Biomarkers in Participants Undergoing Targeted Lung Health Checks (ALPINE)

Lung Cancer

United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris
Roche Pharma AG

Recruiting

Implementing Precision Medicine in cOmmunity HospiTALs (PRISM-POrTAL)

Metastatic Cancer

France
SamanTree Medical SA
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Breast Cancer Detection in Breast Surgical Specimens With the Histolog Scanner, Slide-free Confocal Microscope (Hibiscuss)

Breast Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Active, not recruiting

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Primary Mediastinal Large B Cell Lymphoma

France, Belgium, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
Centre Leon Berard
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance

Sarcoma | Gastro-intestinal Stromal Tumors (GIST)

France
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche

Terminated

Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

Burkitt Lymphoma

France
Gustave Roussy, Cancer Campus, Grand Paris
BeiGene; C2i Genomics

Not yet recruiting

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (UMBRELLA)

Soft Tissue Sarcoma | Cancer | Lung Cancer | Pancreas Cancer | Colo-rectal Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche

Recruiting

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program)

Breast Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo, Inc.

Recruiting

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS-BREAST)

Metastatic Breast Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo, Inc.

Recruiting

Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer (ICARUS-LUNG01)

Metastatic Lung Cancer

France
Institut Curie
AstraZeneca; Gustave Roussy, Cancer Campus, Grand Paris

Completed

Chlorhydrate of Ropivacaine and Breast Cancer Surgery

Breast Neoplasms | Pain,Postoperative

France
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche

Unknown

Bevacizumab in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Recruiting

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer (PEACE-4)

Prostate Cancer

France, Switzerland
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Terminated

Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (VERITAS)

Very High Risk Neuroblastoma

Italy, Austria, France, Netherlands, Spain
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Completed

Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP (GEFCAPI04)

Neoplasms, Unknown Primary

Denmark, France, Netherlands
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Completed

Study to Validate a Model of Surgical Deescalation in Atypicals Breast Lesions (NOMAT01)

Breast Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery

Colorectal Cancer | Metastatic Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Unknown

Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients (Estimabl)

Thyroid Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Recruiting

AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy (NANOCOL)

Gynecologic Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Recruiting

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART)

Pediatric Cancer

Italy, France, Denmark, Germany, Netherlands, Spain, United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Active, not recruiting

Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma (SURVEILL'ORL)

Head and Neck Squamous Cell Carcinoma

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Suspended

Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases (PACHA-01)

Colorectal Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Unknown

Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma (MEDINDUCTION)

Head and Neck Cancers

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Completed

Image Guided Radiation Therapy For Prostate Cancer

Prostate Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Completed

Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers (HPV-RX)

Cervical Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy

Cervical Cancer | Precancerous Condition

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Recruiting

Two Chemotherapy Regimens Plus or Minus Bevacizumab (BETTER2)

Pancreatic Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Completed

Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer (IRCIS)

Breast Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer

Colorectal Cancer | Primary Peritoneal Cavity Cancer | Carcinoma of the Appendix

France
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Lung Cancer

France
Assistance Publique - Hôpitaux de Paris
Gustave Roussy, Cancer Campus, Grand Paris

Not yet recruiting

Calprotectin, a Biomarker of COVID-19 Severity (CALPRO) (CALPRO)

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Old Age | Severe/Moderate Coronavirus

France
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC

Not yet recruiting

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc)

Cancer

France
University Hospital, Strasbourg, France
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors (RAPIRI)

Refractory Solid Tumors in Children

France
Memorial Sloan Kettering Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma

Thyroid Cancer

United States
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC

Completed

Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab (PANDORE)

Bladder Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris
Ministry of Health, France

Completed

Confocal Micro-endoscopy in Head and Neck Cancer/Micro Endoscopie Confocale (MEC)Oto-Rhino-Laryngologie (ORL) (MEC ORL)

Malignant Pharyngo Laryngeal Tumors | Pre-malignant Pharyngo Laryngeal Tumors

France
Gustave Roussy, Cancer Campus, Grand Paris
Ministry of Health, France

Completed

Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract (JANORL2)

Squamous Cell Carcinoma

France

Clinical Trials Sponsored by Gustave Roussy, Cancer Campus, Grand Paris

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations